Meeting
2018 Genitourinary Cancers Symposium
Discordance rate of PD-L1 expression between primary and metastatic lesions in urothelial carcinoma (UC).
Authors
Earle Frederick Burgess
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC
Earle Frederick Burgess , Caroline Naso , Shannon Doherty , Renato Guerrieri , Chad Livasy , Aaron Hartman , Myra M. Robinson , James Thomas Symanowski , Claud Grigg , David L. Graham , Kwabena Osei-Boateng , Stephen Boyd Riggs , Peter Clark , Derek Raghavan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 493)
DOI
10.1200/JCO.2018.36.6_suppl.493
Abstract #
493
Poster Bd #
J22
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.
First Author: Weihua Guo
Poster
2020 ASCO Virtual Scientific Program
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.
First Author: Sarah Verhoeff
Poster
2019 Genitourinary Cancers Symposium
Analysis of real-world PD-L1 testing in patients with urothelial carcinoma.
First Author: Gabriel S Krigsfeld
Poster
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
First Author: Mathilde Cancel